ZuriMED obtains the Innosuisse Certificate


The Zurich based startup ZuriMED, specialising in orthopaedic biomechanics, has earned the Innosuisse certificate, thanks to its revolutionary device for ligament reconstruction. The company’s Bone-Tendon-Bone (BTB)-Converter™ is currently undergoing a clinical trial.


Founded in 2015, ZuriMED is developing a device for surgical knee ligament reconstruction, the BTB-Converter™. The idea behind the new surgical technique it to effectively convert a less painful hamstring autograft (a patient’s own tissue), or any other flexible graft, into a higher performance BTB-like graft. According to Xiang Li, Co-founder and CEO of ZuriMED, there has been a change from the original design in the product development. He says, “Due to the EU regulatory environment transition, our original strategy of having a complete, preassembled BTB-Conversion-Kit™ has changed: we would now have two separate implants, which could be assembled during surgery.” The first component of the kit, the BTB-Converter™ is currently under clinical trial at University Hospital Balgrist, which started in 2017, and is scheduled to complete by early 2021. The second component, the product VariLoop™ is expected to enter into clinical trial next year.”The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. In acknowledgement of the receipt of this accolade, Xiang comments: “We see the Innosuisse certificate as a valuable label accredited by external experts for the work we have done in the past. Besides being a label that we could proudly present to our current investor, we believe that this certificate would certainly help us during the due diligence for a potential future financing round.” The roadmap to the futureSince its foundation, the company had been operating with a lean core team. With a ‘CTI’ now (innosuisse) project grant, the company expanded its team. In 2016, additional funds in a seed round were obtained. The ZuriMED team is currently focusing on product development and clinical validation. Upon completion, the company will seek a licencing agreement to foster quick technology transfer with bigger medtech companies that will commercialise the products. As revealed by the company, there is a strong interest in the medical device companies and discussions are underway. Regarding its future developments Xiang elucidates that although the company began with products for the knee ligament reconstruction, the technologies could also be used for other indications such as in the shoulder, hand, foot, ankle, and other regions in the body. Therefore, the company plans to expand the technology into these indications and aims to have a complete licensable portfolio by 2022.(RAN)Photo L-R:Elias Bachmann, Jess Snedeker, Xiang Li